

# Edith A Perez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/961637/publications.pdf>

Version: 2024-02-01

29  
papers

6,663  
citations

279487

23  
h-index

454577

30  
g-index

32  
all docs

32  
docs citations

32  
times ranked

9410  
citing authors

#	ARTICLE	IF	CITATIONS
1	Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE. <i>Cancer</i> , 2019, 125, 3974-3984.	2.0	67
2	Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. <i>BMC Cancer</i> , 2019, 19, 517.	1.1	42
3	Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 141-148.	0.8	327
4	Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breast Tumors from the NCCTG (Alliance) N9831 Trial. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw207.	3.0	26
5	PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). <i>Npj Breast Cancer</i> , 2016, 2, .	2.3	80
6	Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results. <i>Breast Cancer Research</i> , 2016, 18, 126.	2.2	58
7	Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw037.	3.0	24
8	Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 56.	3.4	183
9	Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring an ERBB2 S310F Mutation. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1066-1070.	2.3	31
10	Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 701-708.	0.8	171
11	Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 2600-2608.	0.8	91
12	Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2353-2360.	0.8	167
13	Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). <i>Journal of Clinical Oncology</i> , 2015, 33, 2361-2369.	0.8	197
14	Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane. <i>Journal of Clinical Oncology</i> , 2015, 33, 594-601.	0.8	365
15	The Globalization of Cooperative Groups. <i>Seminars in Oncology</i> , 2015, 42, 693-712.	0.8	6
16	Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831. <i>Journal of Clinical Oncology</i> , 2014, 32, 3744-3752.	0.8	771
17	Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer. <i>Breast Cancer Research</i> , 2014, 16, R50.	2.2	49
18	Dual HER2 blockade: preclinical and clinical data. <i>Breast Cancer Research</i> , 2014, 16, 419.	2.2	11

#	ARTICLE	IF	CITATIONS
19	Biomarker Testing for Breast, Lung, and Gastroesophageal Cancers at NCI Designated Cancer Centers. Journal of the National Cancer Institute, 2014, 106, .	3.0	18
20	Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2014, 32, 2100-2108.	0.8	165
21	Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance). Journal of Clinical Oncology, 2014, 32, 2311-2317.	0.8	70
22	Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Journal of Clinical Oncology, 2013, 31, 3997-4013.	0.8	3,276
23	Impact of PTEN Protein Expression on Benefit From Adjuvant Trastuzumab in Early-Stage Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer in the North Central Cancer Treatment Group N9831 Trial. Journal of Clinical Oncology, 2013, 31, 2115-2122.	0.8	104
24	Current and emerging targeted therapies for metastatic breast cancer. Cancer, 2012, 118, 3014-3025.	2.0	42
25	<i>HER2</i> and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial. Journal of Clinical Oncology, 2010, 28, 4307-4315.	0.8	216
26	Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer. Breast Cancer Research and Treatment, 2009, 114, 195-201.	1.1	83
27	Adjuvant Chemotherapy: Controversies and the Role of Taxanes. Breast Journal, 2003, 9, S25-S28.	0.4	2
28	Management of Bone Metastases in Advanced Breast Cancer. Cancer Control, 1999, 6, 28-31.	0.7	2
29	Utility of screening procedures for detecting recurrence of disease after complete response in patients with small cell lung carcinoma. Cancer, 1997, 80, 676-680.	2.0	15